Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Invex Therapeutics Ltd. ( (AU:IXC) ) is now available.
Invex Therapeutics Ltd has announced that its Annual General Meeting (AGM) will be held on November 25, 2025, with director nominations closing on October 7, 2025. This announcement is significant for stakeholders as it outlines the timeline for key governance activities, which could impact the company’s strategic direction and leadership.
More about Invex Therapeutics Ltd.
Invex Therapeutics Ltd is a biopharmaceutical company that focuses on repurposing the approved drug Exenatide for treating neurological conditions involving raised intracranial pressure, such as acute stroke and traumatic brain injury. The company has trademarked its repurposed Exenatide as Presendin™.
Average Trading Volume: 69,125
Technical Sentiment Signal: Buy
Current Market Cap: A$12.02M
See more insights into IXC stock on TipRanks’ Stock Analysis page.